Stock Analiz

Myomo, Inc. MYO

Industrial Specialties · IPO 2017 · data as of November 13, 2026

$1.23Market cap $49M
Open the interactive analysis →

Myomo, Inc. (MYO) is a healthcare company listed in the US with a market value of about $49M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$15M, a net margin of -33.1%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 40% a year, a 5-year average ROIC of -58%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.

About Myomo

Myomo is listed in the US and classified in industrial specialties, IPO year 2017. Revenue went from $1M in 2016 to $41M in 2025, growth of about 49.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 494% over three years (dilution for shareholders). It spends 17% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.1
P/B17.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-13.8%
Shareholder yield0.0%
Intrinsic value vs. price−60%

Growth and quality

Revenue growth (1 yr)25.7%
Revenue growth (5 yrs, per year)40.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-48.6%
ROIC (5-yr avg.)-58.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$46M$41M$33M$19M$16M$14M$8M$4M$2M$2M$1M
Net income-$15M-$16M-$6M-$8M-$11M-$10M-$12M-$11M-$10M-$12M-$4M
Free cash flow-$7M-$16M-$5M-$6M-$10M-$10M-$9M-$10M-$10M-$6M-$3M
EPS (diluted)$-0.35$-0.37$-0.16$-0.28$-1.52$-1.89$-3.67$-20.79$-25.18$-87.90$-123.90
Net margin-33.1%-38.0%-19.0%-42.3%-68.9%-74.9%-152.5%-279.2%-422.1%-776.0%-327.8%
ROIC—-37.0%-13.7%-67.8%-122.0%-50.2%-70.7%-93.9%-129.4%-41.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Myomo stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Myomo pay a dividend?

Not currently.

Is Myomo a good stock to buy?

We do not give buy or sell advice. Myomo scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.